3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
3
Status
Completed
2
Terminated
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Dermatologic
7
Genitourinary
3
Sarcoma
2
Gastrointestinal
2
Breast
2
Thoracic
1
Other hematologic neoplasm
1
Lymphoid
1
Head & Neck
1
CNS
1
Conditions
Carcinoma, Renal Cell
4
Neoplasm Metastasis
3
Melanoma
3
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Transitional Cell
2
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Recurrence
1
Metastatic Castration-resistant Prostate Cancer
1
Kidney Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Interventions
pembrolizumab
75
Nivolumab
46
Cyclophosphamide
25
aldesleukin
23
fludarabine
16
atezolizumab
15
Ipilimumab
15
Interleukin-2
14
Radiosurgery
13
Paclitaxel
13
Specimen Handling
12
Magnetic Resonance Spectroscopy
11
Carboplatin
11
fludarabine phosphate
9
Docetaxel
9
durvalumab
8
Cisplatin
8
cemiplimab
7
Bevacizumab
7
Radiotherapy
6
Gemcitabine
6
Biopsy
6
spartalizumab
5
avelumab
5
Pemetrexed
5
Oxaliplatin
5
Immune Checkpoint Inhibitors
5
Filgrastim
5
Cryosurgery
5
Blood Specimen Collection
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Melanoma
×
bempegaldesleukin
×
Genitourinary
×
Clear all
NCT03548467
2023-04-21
DIRECT-01
Nykode Therapeutics ASA
Phase 1/2
Completed
41 enrolled
NCT02983045
2023-03-13
PIVOT-02
Nektar Therapeutics
Phase 1/2
Completed
557 enrolled
22 charts
NCT03435640
2023-03-08
REVEAL
Nektar Therapeutics
Phase 1/2
Terminated
64 enrolled
22 charts